1 2 3
Developing therapies for patients
with serious, ultra-rare diseases

LEAD PROGRAM

We are working to obtain FDA approval for EDSIVO™

Treatment of vascular Ehlers-Danlos Syndrome

Acer is committed
to supporting patients
and families that need it most.

PIPELINE

We are developing ACER-001

The first potential therapy for Maple Syrup Urine Disease

(MSUD); and the Urea Cycle Disorder (USD)

Acer is changing the path
to managing rare diseases

INVESTORS

Analyst Converage

Investor FAQs

QUICK
NAV